✦ LIBER ✦

P-281 Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA)

✍ Scribed by Braun, T.; Raffoux, E.; Prebet, T.; Stamatoullas, A.; Bréchignac, S.; Dreyfus, F.; Samey, B.; Adès, L.; Vey, N.; Dombret, H.; Fenaux, P.; Gardin, C.

Book ID: 121967656
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 68 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/S0145-2126(13)70328-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a multicenter phase II trial

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

✍ Florian Heidel; Jorge Cortes; Frank G. Rücker; Walter Aulitzky; Laurie Letvak; T 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views